Nu Holdings Faces Valuation Test Ahead of Mexico Bank Launch
Analysis Daniel Marsh

Nu Holdings Faces Valuation Test Ahead of Mexico Bank Launch

Nu Holdings (NU) rose 1.7% last week, but its valuation remains stretched at 22.1x trailing earnings. Mexico bank launch and rate decision loom.

NU INTR
SK hynix ADR Premium Narrows to 21% After Seoul Shares Surge
Markets Daniel Marsh

SK hynix ADR Premium Narrows to 21% After Seoul Shares Surge

SK hynix shares surged 30% in Seoul, narrowing the ADR premium to ~21%. Q2 results missed estimates on HBM4 delays, but demand stays robust.

MU AMD
BP's North Sea Exit Could Cover 13% of $20B Divestment Goal
Earnings James Calloway

BP's North Sea Exit Could Cover 13% of $20B Divestment Goal

BP's planned North Sea divestment, valued at $2B-$2.6B, could cover up to 13% of its $20B asset sale target, ahead of Q2 earnings where net debt is forecast at $22-$23B.

BP SHEL TTE USO
Bristol Myers Squibb at Crossroads as AstraZeneca Merger Talks Surface
Markets Daniel Marsh

Bristol Myers Squibb at Crossroads as AstraZeneca Merger Talks Surface

Bristol Myers Squibb shares rose 5.2% last week after strong Q2 earnings, but a reported $400B merger approach from AstraZeneca puts the stock in focus Monday.

BMY AZN PFE
American Airlines' $1.6B Fuel Hit Raises Margin Concerns
Earnings James Calloway

American Airlines' $1.6B Fuel Hit Raises Margin Concerns

American Airlines faces a $1.6 billion fuel cost increase, equal to 15.8% of its market value, intensifying concerns over its profit conversion gap.

AAL DAL UAL
Alphabet's $119B AI Bet Puts Rebound at Risk
Analysis Daniel Marsh

Alphabet's $119B AI Bet Puts Rebound at Risk

Alphabet's recovery faces a crucial test as it plans $119B in AI spending, potentially straining cash flow despite strong cloud growth. Markets watch AMD earnings and jobs data.

GOOGL AMD MSFT AMZN
AZN-BMY Merger Talks: A $455B Pharma Mega-Deal in the Making?
Analysis Daniel Marsh

AZN-BMY Merger Talks: A $455B Pharma Mega-Deal in the Making?

AstraZeneca and Bristol Myers Squibb are reportedly in merger talks, which could create a $455 billion pharmaceutical giant. Reuters has not confirmed the report.

AZN BMY ABBV MRK LLY JNJ NVS
Rivian's R2 Ramp Demands 74% Delivery Surge; Shares Tumble 9.6%
Earnings James Calloway

Rivian's R2 Ramp Demands 74% Delivery Surge; Shares Tumble 9.6%

Rivian's shares dropped 9.6% despite Q2 revenue and earnings beating estimates, as the company's R2 delivery ramp requires a 74% increase in second-half deliveries.

RIVN TSLA LCID
GM Stock Surges 7.5% on Strong Sales, But Valuation Gap with Ford Narrows Slowly
Markets Daniel Marsh

GM Stock Surges 7.5% on Strong Sales, But Valuation Gap with Ford Narrows Slowly

GM shares gained 7.5% last week, yet its valuation multiple still trails Ford's. Strong Q2 margins and raised guidance support the stock, but the gap remains.

GM F STLA
IonQ's $1.8B SkyWater Deal Reshapes Valuation Metrics
Earnings James Calloway

IonQ's $1.8B SkyWater Deal Reshapes Valuation Metrics

IonQ's acquisition of SkyWater Technology boosts revenue base, cutting its price-to-sales ratio from 51 to 19, yet shares remain richly valued. Q2 earnings due Wednesday.

IONQ SKYT QBTS RGTI QUBT
Micron Shares Slide 10.6% Amid Memory Price Concerns
Earnings James Calloway

Micron Shares Slide 10.6% Amid Memory Price Concerns

Micron shares dropped 10.6% last week, even as the company projected strong Q4 growth, reflecting investor concerns about peak memory pricing.

MU SNDK AAPL AMZN AMD
Raising Cane's August Expansion Plan Signals Shift in Chicken Brand Growth
Analysis Daniel Marsh

Raising Cane's August Expansion Plan Signals Shift in Chicken Brand Growth

Raising Cane's will open seven new restaurants in August, including two in new markets, as the chicken chain aims for 100 openings in 2026.

WING YUM QSR